Patrys Limited
ASX:PAB.AX
0 (AUD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Patrys Limited |
Symbool | PAB.AX |
Munteenheid | AUD |
Prijs | 0.003 |
Beurswaarde | 6,172,350 |
Dividendpercentage | 0% |
52-weken bereik | 0.003 - 0.011 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. James A. Campbell B.Sc., MBA, Ph.D. |
Website | https://www.patrys.com |
An error occurred while fetching data.
Over Patrys Limited
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)